Drawing for EPIGENESIS PHARMACEUTICALS EE

USPTO serial 77585606

EPIGENESIS PHARMACEUTICALS EE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
NADELMAN, ANDREA KOYNER
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EPIGENESIS PHARMACEUTICALS EE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostateACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 20, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 20, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 5, 2011WOAGWITHDRAWAL OF ATTORNEY GRANTED—
May 5, 2011WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED—
Nov 6, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 5, 2010EX3GSOU EXTENSION 3 GRANTED—
Nov 4, 2010EXT3SOU EXTENSION 3 FILED—
Nov 4, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 4, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 3, 2010EX2GSOU EXTENSION 2 GRANTED—
Jun 3, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 17, 2010EXT2SOU EXTENSION 2 FILED—
May 17, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 3, 2009EX1GSOU EXTENSION 1 GRANTED—
Nov 3, 2009EXT1SOU EXTENSION 1 FILED—
Nov 3, 2009EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 19, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 24, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 4, 2009NPUBNOTICE OF PUBLICATION—
Jan 22, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 22, 2009ALIEASSIGNED TO LIE—
Jan 6, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 6, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Jan 6, 2009GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 6, 2009GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 6, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 30, 2008DOCKASSIGNED TO EXAMINER—
Oct 8, 2008MPMKNOTICE OF PSEUDO MARK MAILED—
Oct 7, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance